VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering

By adminDecember 22, 2020Global News Feed

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its $100 million underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen.

Originally posted here:
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering

Quotient Limited Announces Departure of Chief Operating Officer

By adminDecember 22, 2020Global News Feed

JERSEY, Channel Islands, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that on December 21, 2020, Ed Farrell delivered a notice of resignation from his position as the Company's Chief Operating Officer. Under Mr. Farrell's employment agreement, unless the Company elects otherwise, the resignation will take effect 12 months after the notice was given. Mr. Farrell stated that his resignation was due to personal reasons.

Read the original post:
Quotient Limited Announces Departure of Chief Operating Officer

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

By adminDecember 22, 2020Global News Feed

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company’s board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and corporate strategy.

More here:
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

GENFIT: Renegotiation of the OCEANEs Convertible Bond Terms: Availability of Prospectus Relating to the Admission of New Shares Following Conversion…

By adminDecember 22, 2020Global News Feed

Lille (France), Cambridge (Massachusetts, United States), December 22, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases (the “Company”), today announces that is has filed with the French Autorité des marchés financiers (the “AMF”) an amendment to its 2019 Universal Registration Document and that the AMF has approved on December 22, 2020 under the approval no. 20-616 a prospectus (the “Prospectus”) made available to the public in connection with the admission on the regulated market of Euronext in Paris (“Euronext Paris”) of a maximum aggregate of 17,522,016 new ordinary shares, each with a nominal value of €0.25 to be issued following the potential full bond conversion in accordance with the Conversion Ratio Modification (as defined below), of 3,185,821 convertible bonds into new shares and/or exchangeable for existing shares that would remain outstanding following the Partial Buyback (as defined below), which were issued by the Company on October 16, 2017 and due October 16, 2025, provided that the Bondholders accept to postpone the maturity date of the OCEANES (the “OCEANEs”).

See the article here:
GENFIT: Renegotiation of the OCEANEs Convertible Bond Terms: Availability of Prospectus Relating to the Admission of New Shares Following Conversion...

Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

By adminDecember 22, 2020Global News Feed

CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold on the RESTORE-1 clinical trial of NBIb-1817 (VY-AADC). As previously announced, trial sites participating in RESTORE-1 had not been screening, enrolling or dosing patients as a result of the COVID-19 pandemic and more recently, as a result of the independent Data Safety Monitoring Board (DSMB)’s request to pause dosing pending its review of additional data. The DSMB has requested additional patient level data from the trial and now plans to review these data in early 2021. The clinical hold follows the submission by Neurocrine Biosciences of an IND Safety Report related to the observation of MRI abnormalities in some RESTORE-1 study participants. The clinical implications of this observation are currently unknown and are being evaluated.

Link:
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

Translate Bio Announces Departure of Chief Financial Officer

By adminDecember 22, 2020Global News Feed

LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schroer, the Company’s Chief Financial Officer (CFO), is departing the Company for personal reasons. Mr. Schroer's departure will be effective by year-end 2020. Robert Prentiss, Translate Bio’s Vice President and Corporate Controller since 2017, will serve as Principal Accounting Officer and report directly to the Company’s Chief Executive Officer, Ronald Renaud, on an interim basis while a formal search process to appoint a new CFO is conducted.

Here is the original post:
Translate Bio Announces Departure of Chief Financial Officer

Zenith Announces Voting Results from the 2020 Annual and Special Meeting of Shareholders

By adminDecember 22, 2020Global News Feed

CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp. ("Zenith" or the "Company") announces that, at its annual and special meeting of shareholders held earlier today, Zenith shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 9, 2020 (the Information Circular), which is available on SEDAR at www.sedar.com, and on the Zenith website at www.zenithepigenetics.com.

Continued here:
Zenith Announces Voting Results from the 2020 Annual and Special Meeting of Shareholders

Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen

By adminDecember 22, 2020Global News Feed

CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta.

Original post:
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen

Harvard Bioscience Announces New Credit Facility

By adminDecember 22, 2020Global News Feed

HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 million credit facility (the “Refinancing”). Proceeds from the new facility will be used to retire existing debt and pay related fees and expenses. The Refinancing significantly reduces borrowing costs while increasing operating flexibility through less restrictive financial covenants and access to higher levels of revolver borrowings.

Original post:
Harvard Bioscience Announces New Credit Facility

Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

By adminDecember 22, 2020Global News Feed

ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).

See the original post:
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD